Hodson 1985.

Methods	Study design: parallel RCT Time frame: not reported Follow‐up period: 12 months (0.6 to 1.2 years) Loss to follow‐up/excluded: probably 37% (9/24); unclear but only 15 included in analysis
Participants	Country: Australia Setting: Single centre CKD including dialysis; documented bone disease on histology Number (randomised/analysed): treatment group (13/8); control group (11/7) Age: not reported Sex (M/F): 14/10 Exclusion criteria: not reported
Interventions	Treatment group Calcitriol: 15 ng/kg/d for 12 months, increased till Ca reached 2.6. Final dose 5 to 30 ng/kg/d Control group Ergocalciferol: 0.25 mg/d for 12 months, increased till serum Ca reached 2.6 Final dose 25 to 100 µg/kg/d Co‐interventions Dialysis (9); bicarbonate supplements; aluminium‐containing phosphate binders
Outcomes	Bone histology Bone radiology, bone age Growth cm/y: % expected for bone age Biochemistry: PTH, ALP, Ca, P
Notes	Number of exclusions unclear. Reported that 6/24 excluded (4 calcitriol, 2 ergocalciferol) but only 15/24 analysed so 9/24 excluded Only patients undergoing pre and post biopsies were included
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Systematic ranking design in blocks of 4 based on severity of bone histology changes
Allocation concealment (selection bias)	High risk	Investigators aware of blocks so could influence next entry
Blinding of participants and personnel (performance bias) All outcomes	High risk	No Blinding. Lack of blinding could influence patient management
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Laboratory based outcomes
Incomplete outcome data (attrition bias) All outcomes	High risk	9/24 (38%) excluded from final analysis
Selective reporting (reporting bias)	Low risk	All outcomes reported
Other bias	Low risk	No evidence of other bias